Taiho Pharmaceutical Co. Ltd.
TOKYO, July 22, 2011 -
- Positive Results of Overall
Survival in Patients with Colorectal Cancer Refractory to Standard
Chemotherapy -
Taiho Pharmaceutical Co., Ltd.
TOKYO, March 14, 2011 - Taiho Pharmaceutical Co., Ltd., and its parent company, Otsuka Holdings
Co., Ltd., announced today that the European Commission (EC) has granted
marketing authorization for Teysuno(TM) (S-1), a novel oral anti-cancer agent
indicated for the treatment of adults with advanced gastric cancer when given
in combination with cisplatin.
TOKYO, December 17, 2010 - Taiho Pharmaceutical Co., Ltd., and its parent company, Otsuka Holdings
Co., Ltd., announced today that the Committee for Medicinal Products for
Human Use (CHMP), a division of the European Medicines Agency (EMA), has
issued an opinion recommending approval of Teysuno(TM) (S-1), a novel oral
anti-cancer agent, intended for the treatment of advanced gastric cancer in
adults when given in combination with cisplatin.
